Figure 5 from Decoding the Genomic and Functional Landscape of Emerging Subtypes in Ovarian Cancer
Year: 2025
Type: other
Abstract: Subtype characterization. A, Uniform Manifold Approximation and Projection (UMAP) of scRNA-seq cancer cell profiles from the full dataset of 57 patients, colored by patient. B, UMAP of scRNA-seq profiles from the 57 patients colored by cell type. C, Pathway activities of proliferative subtype samples from analysis of the primary and metastatic tissues. The bar color represents the regulation direction of the pathway, the white stripes pattern indicates nonsignificant results, and the stroke highlights the characterizing pathways (pathways that exhibit the same directional trend in both tissue compartments). D, Proliferation score distribution across the core, EMT, and proliferative subtypes, calculated as the proportion of cells in S and G2/M cell-cycle phases per scRNA sample. Colors represent quantiles, white diamonds indicate median scores, and the red dashed line marks the proliferative HRP reference. Gray densities show the overall score distribution within each subtype. E, Progeny-derived weights and t-values from differential expression analysis (DEA) of hypoxia target genes in metastatic samples of the proliferative subtype. Red dots represent significantly upregulated genes, whereas blue dots indicate downregulated genes. F, Distribution of epithelial ovarian cancer (EOC), fibroblast, and immune cell counts across tissue areas (primary and metastatic) for the HRP subtypes. Notably, metastatic EMT subtype samples display a significantly higher proportion of fibroblasts than the other HRP subtype (Mann–Whitney U test, P = 0.02). G, IC50 values for HRP cell lines from the GDSC1 drug screen (ES2, NIHOVCAR3, FUOV1, JHOS2, and OV90). Compounds targeting the G2/M cell-cycle checkpoint and histone deacetylase (HDAC) inhibitors are highlighted. HRP cells exhibit sensitivity to both classes of compounds, suggesting a potential vulnerability associated with G2/M checkpoint regulation. H, Viability of patient-derived organoids (PDOs) after prexasertib delivery in two concentrations. Notably, core HRP and BRCA2-like HRD subtypes are sensitive, whereas EMT HRP is resistant.
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4415787091